'r--------"'T'"---------------., 6.02E7
l OC
90 j
A
1'2
~
60
OJ
70
" c:
""
'" 60
c:
:>
~
OJ
50
- ~
"'
a;
(l:
10
0
10
20
100
90
C
80
Peptide T4
~
~ 70
MS/MS
1:>
3 so
~
! 50
>
~ 40
~ Jo l
y'f
~H.
I
20
_ I , y6 b7
10
1 p'~
U
J
0 .,
i.JJe~ll~oI.~I~J
400
600
800
T4
TIC +
c Full ms ( 350,00 - 2000.00)
T
K
AD =
Tryptic pept ide
Kerat
in
A lItod i
gestion
product
30
40
50
so
70
Time (min)
y6
S#: 857-877 +
c d
Full ms2
1105,79 [ 290 _00 - 2000,00J
LQAQNQWLQDMTTHLlLR
)'10 yl 1
y12
)'13
011
2,22E5
1000
1200
1400
1600
1800
2000
100
90
80
OJ
u
c:
70
""
"0
c:
:l
60
.0
..:
OJ
50
~
"iij
a;
40
(l:
30
20
10
o
B
T2
TIC +
cd Fu ll
MS/MS
~
T4
T5
AD
l AD
~
T "
TI
I~
+
~j~~ U
~ J . . III
~d
10
20
30
40
50
Time (min)
D
SUMMARY2r1TML V,O (fo,
SEQUEST22 oU ' pu t),
Copyrigbt 1996 Mokcula, Biotechnology,
Univ. of Washington, LEng/J , Yates
Licensed 10
Finnigan MAT
I.
pi, IIL6 HUMAN 74 (7,0,0,1,0)
2.
pi' TRY I BOVIN 30 (3 ,0,0,0,0)
3. pi' STMACYB2
26(1, 1, 1,0,1)
4. pi' K2CI _ HUMAN 20 (2,0,0,0,0)
5_ pi, K 1 CI _HUMAN 20 (2,0,0,0,0)
60
70
377E7
::a
III
<
III
;;1
;;:
;Z
III
...
...
...
:;r
III
~
...
oj'
:;"
...
o
- ~
o
...
III
:;"
o
=
'"
;:::.
;;
."
=o
;;;
~.
C'I
III
;;;
~